Novo Nordisk’s (NVO) stock has dropped by 25% in March (on the Copenhagen exchange) to put it on track for its biggest ...

Novo Nordisk said Thursday that the rampant growth of the U.S.’ compounded drug industry was hurting Wegovy sales, and warned ...

LONDON (Reuters) -Novo Nordisk shares have fallen 25% so far in March and are on track for their biggest monthly drop since ...

And speaking of dividends, Novo Nordisk pays one, and it has increased its annual dividend per share by almost 284% in the ...

The price of SAP shares increased by 1.6 percent, reaching EUR 170.50, which brought the company's market capitalization to ...

Novo Nordisk leads a GLP-1 agonist market that could surpass $150 billion by 2035. Ironically, the market is passing on the ...

Novo Nordisk is taking aim at Eli Lilly with a new obesity drug deal. Meanwhile, a survey shows doctors’ perception of the ...

Novo Nordisk has acquired the global rights to China-based United Laboratories’ triple-agonist weight-loss and diabetes drug ...

The pivot to the cloud has led to a big rally in SAP stock.

Management software triumphs over slimming injections and insulin The maker of expensive management software, whose ...

It was only a matter of time until the GLP-1 receptor agonist drugs like Ozempic and Wegovy were superseded, and now it looks ...

Novo Nordisk A/S (NYSE:NVO) is a leading global healthcare company that specializes in diabetes care and other chronic ...